Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07252232)

🧪 Interventions in This Study

• daraxonrasib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (66 Sites)

Showing the first 25 of 66 sites.

• Mayo Clinic — Phoenix, Arizona
• UC San Diego Moores Cancer Center — La Jolla, California
• Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
• University of California, Los Angeles — Los Angeles, California
• Stanford Cancer Institute — Palo Alto, California
• University of California, San Francisco — San Francisco, California
• Rocky Mountain Cancer Centers, LLP — Lakewood, Colorado
• Hartford Healthcare — Hartford, Connecticut
• Mayo Clinic — Jacksonville, Florida
• University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center — Miami, Florida
• Florida Cancer Specialists — St. Petersburg, Florida
• Winship Cancer Institute, Emory University — Atlanta, Georgia
• Community Health Network — Indianapolis, Indiana
• University of Kansas Medical Center Research Institute, Inc. — Lawrence, Kansas
• Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts
• Mayo Clinic Cancer Center — Rochester, Minnesota
• Saint Luke's Cancer Institute — Kansas City, Missouri
• University of Nebraska Medical Center — Omaha, Nebraska
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
• Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center — New York, New York
• Columbia University Medical Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• University of Rochester Medical Center — Rochester, New York

📞 Contact the Study Coordinator

Phone: (480) 342-4800

Email: bekaii-saab.tanios@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pancreatic Cancer

• A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
• Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer — Baltimore, Maryland
• Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma — Hartford, Connecticut
• Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer — Philadelphia, Pennsylvania
• Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Basking Ridge, New Jersey
• Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas — Baltimore, Maryland

Explore by condition: All Pancreatic Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.